Noze develops a handheld diagnostic breathalyzer, DiagNoze®, that uses digital odor perception to detect and identify disease biomarkers in breath. The device aims to enable real-time detection of cancers, infectious diseases, and other clinical conditions without blood draws or lab equipment. DiagNoze is described as low-cost, fully portable, and completely noninvasive, designed for point-of-care and home use. The company says its digital nose performs in real-world settings with precision. Noze intends to use the new funding to further develop its disease detection platform and deploy it in low- and middle-income countries. The company is based in Montreal, Canada. Noze develops DiagNoze®, a handheld breathalyzer that uses digital odor perception, machine intelligence, and a sensor developed with exclusively licensed NASA technology to detect and identify breath-based biomarkers in real-world settings. The company positions its technology for rapid, cost-effective screening and real-time disease detection at point-of-care, with a stated mission to improve patient outcomes and enable universal access. Noze received grant support from the Bill & Melinda Gates Foundation, bringing total Gates grant funding to $1.8 million. The latest grant will fund a clinical study aimed at detecting tuberculosis in high-burden countries, with the company planning to begin the study in fall 2024. Leadership highlights include CEO Karim Aly, who emphasized the technology’s potential to expand diagnostic access in remote and underserved communities. The company is based in Montreal. Noze develops a portable breathalyzer powered by an AI-based digital odour perception platform that detects unique biomarkers in exhaled breath to recognize infectious diseases such as tuberculosis and malaria. The device is intended to deliver instant, non-invasive diagnostics and is slated for completion by the end of 2023, after which it will enter clinical validation. Noze uses exclusively licensed patents from NASA and says its platform was used during the COVID-19 pandemic to track airborne markers from infected individuals. The company positions breath-based diagnostics as a tool to improve healthcare accessibility and to scale worldwide. Noze has partnered with the Montreal Heart Institute on a project called “Paradigm Shift in the Conduct of Clinical Trials,” and that MHI consortium received a $9.35 million grant from Quebec’s Ministry of Economy and Innovation plus $12.3 million in private partner investments. To date Noze has received C$24.4 million in funding from investors including TandemLaunch, Mistral Venture Partners, Fonds Innovexport, and Creative Destruction Labs.

Total raised

$6M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2024